# This super composite rating is the result of a weighted average of the rankings based on the following ratings.

*biotech · news · 2026-05-26 · MarketScreener*

## Key points

- The Trader super rating uses EPS Revisions from only the last 4 months in its calculation.
- The Investor super rating includes EPS Revisions over a full 1-year period for its ranking.
- The Global composite rating requires company coverage by at least 4 of its 5 rating categories.
- The Quality composite rating can be calculated if the company is covered by at least 2 of 3 categories.

Trader This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions. Investor This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions. Global This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions. Quality This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.

[Read the full story on MarketScreener](https://www.marketscreener.com/news/outlook-therapeutics-says-fda-finds-substantial-evidence-of-effectiveness-for-lytenava-in-namd-ce7f5addde8df324)

---

Canonical: https://newsio.io/n/fa2a44c4-f9d8-4e92-95fc-def7e862b905/this-super-composite-rating-is-the-result-of-a-weighted-average-of-the-rankings
Summarized by Newsio from MarketScreener. https://newsio.io/how-it-works